News

The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future directions that ide-cel research may take.

The phase 3 VITAL study, which is currently enrolling, will evaluate the investigational cell therapy agent further.

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.  

Leo I. Gordon, MD, and others discussed second-line treatment of diffuse large B-cell lymphoma.

Eunice Wang, MD and Bijal Shah, MD, MS, discuss novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.

Investigators found that bilaterally treated participants experienced greater improvements in BCVA than unilaterally treated participants.

The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed overall response rate and stringent complete responses in the CARTITUDE-1 trial.

The director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed how the meeting sets the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

The chief executive officer of FlowMetric discussed the company’s role in supporting the development of novel gene and cell therapies.

Genetically modified oncolytic viruses may provide a new strategy against malignant tumors.

The engineered natural killer cells lack the off-target effects of typical CAR T-cell therapy and similarly lack any concerning safety signals.

The OPTIC phase 1 study showed that the treatment was associated with a significant reduction in treatment burden after 1 injection.

The FDA’s designation follows positive data presented at the 2020 ASH meeting.

The CEO of Avamab Pharma discussed how the field of gene therapy has shifted due to the COVID-19 pandemic.

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed the phase 2 CARTITUDE-2 trial.

The head of neuroscience at Sangamo Therapeutics discussed advances in understanding disease biology that allow for more specific gene targeting.

The phase 3 ZUMA-7 trial met both its primary and secondary endpoints.

The professor of medicine and director of the Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine described the impact of CAR T-cell therapy on the hematologic cancer landscape.

Patients receiving omidubicel also spent less time in hospital following transplant.

The head of neuroscience at Sangamo Therapeutics discussed the potential of ZFPs in central nervous system disorders.

Conversion from MRD positivity to MRD-negative disease in a high-dose patient prompted the expansion of the trial population.

Surveyed oncologists supported the use of CAR T-cell therapy at higher rates than previous years.

A novel combination immunotherapy enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.

Bradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

Interim data from a phase 1 study from Intellia Therapeutics and Regeneron Pharmaceuticals is the first to support in vivo CRISPR genome editing in humans.

Philippe Moreau, MD, discussed the CARTITUDE-1 trial's promising results with ciltacabtagene autoleucel read out at the 2021 ASCO Annual Meeting.

The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed adverse events in the CARTITUDE-1 trial.

The announcement follows positive results from the phase 1/2a trial of MCO-010 for RP.